NCT01652976View on ClinicalTrials.gov

Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

February 28, 2018

Study Completion Date

July 31, 2020

Conditions
Pancreatic Cancer Metastatic
Interventions
DRUG

Dasatinib

Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle

DRUG

mFOLFOX6

mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle

Trial Locations (1)

32610

UF Health Cancer Center, Gainesville

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Florida

OTHER